secwatch.observer — SEC 8-K summary
======================================

Issuer:     Y-mAbs Therapeutics, Inc. (—)
CIK:        0001722964
Form:       8-K
Filed at:   2024-07-19T23:59:59+00:00
Accession:  0001558370-24-009915
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Y-mAbs CFO Bo Kruse to depart July 31; consultancy agreement for transition services through July 2025
--------------------------------------------------------------------------------

- Kruse's last employment day is July 31, 2024; he receives a pro-rated 2024 bonus of $151,376 (DKK 1,035,867).
- Pre-September 28, 2022 equity continues vesting per original terms; post-September 28, 2022 equity vests through July 31, 2025.
- Consultancy via Investeringsselskabet GH ApS begins August 1, 2024 for one year, with a fixed monthly fee of $43,251 (DKK 295,967 excl. VAT).
- Consulting covers financial operations and corporate governance; Kruse must assist with litigation arising from his tenure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1722964/000155837024009915/0001558370-24-009915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1722964/000155837024009915/ymab-20240716x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer